Drug Profile
Research programme: antibody therapeutics - AbbVie / Philogen
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator AbbVie; Philogen
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Inflammation in Italy (Parenteral)
- 28 Feb 2020 No recent reports of development identified for research development in Inflammation in USA (Parenteral)
- 21 Jan 2016 Early research in Inflammation in USA and Italy before January 2016 (Philogen Pipeline, January 2016)